Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Cytarabine,CYT2023-001,2023,USA,MDV,350,62,45,55,26.5,32,85,5,15,30,40,15,55,25,15,5,20,35,30,12,5,3,7,4,25,60,40,FLT3 Inhibitor + Cytarabine,7+3,HiDAC,MEC,0,0,0,35,70,50,15,50,35,65,2
Cytarabine,CYT2023-002,2023,Canada,Claim Database,420,68,48,52,27.1,38,80,6,12,28,42,18,52,28,14,6,18,32,33,14,6,4,8,5,22,58,38,FLT3 Inhibitor + Cytarabine,7+3,HiDAC,MEC,0,0,0,38,72,52,18,48,34,68,2.5
Cytarabine,CYT2023-003,2023,UK,MDV,280,70,50,50,28,40,75,7,10,25,45,20,50,30,12,8,15,30,35,15,7,5,9,6,20,55,35,FLT3 Inhibitor + Cytarabine,7+3,HiDAC,MEC,0,0,0,40,75,55,20,45,35,70,3
